Quent Capital LLC Has $297,000 Holdings in Pfizer Inc. (NYSE:PFE)

Quent Capital LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 26.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,184 shares of the biopharmaceutical company’s stock after selling 4,068 shares during the period. Quent Capital LLC’s holdings in Pfizer were worth $297,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Exchange Traded Concepts LLC boosted its stake in Pfizer by 117.0% in the third quarter. Exchange Traded Concepts LLC now owns 69,178 shares of the biopharmaceutical company’s stock worth $2,002,000 after purchasing an additional 37,293 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. raised its holdings in shares of Pfizer by 28.8% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 23,274 shares of the biopharmaceutical company’s stock valued at $674,000 after buying an additional 5,205 shares during the last quarter. ORG Wealth Partners LLC acquired a new position in Pfizer during the 3rd quarter worth about $115,000. Fiduciary Alliance LLC grew its holdings in Pfizer by 15.5% during the 3rd quarter. Fiduciary Alliance LLC now owns 8,484 shares of the biopharmaceutical company’s stock worth $246,000 after acquiring an additional 1,140 shares during the last quarter. Finally, CX Institutional grew its holdings in Pfizer by 80.1% during the 3rd quarter. CX Institutional now owns 46,207 shares of the biopharmaceutical company’s stock worth $1,337,000 after acquiring an additional 20,552 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on PFE shares. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. UBS Group dropped their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

Pfizer stock opened at $25.53 on Wednesday. The firm has a market capitalization of $144.69 billion, a P/E ratio of 18.11, a PEG ratio of 0.64 and a beta of 0.64. The business has a 50-day moving average of $26.28 and a 200-day moving average of $27.69. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.10 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.74%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.